Your browser doesn't support javascript.
loading
Prekallikrein - an emerging therapeutic target for Klebsiella pneumoniae infection?†.
Lam, Zena; Condliffe, Alison M.
Affiliation
  • Lam Z; Department of Infection, Immunity and Cardiovascular Diseases, University of Sheffield, Sheffield, UK.
  • Condliffe AM; Department of Infection, Immunity and Cardiovascular Diseases, University of Sheffield, Sheffield, UK.
J Pathol ; 250(4): 359-361, 2020 04.
Article in En | MEDLINE | ID: mdl-31943204
Klebsiella pneumoniae is a Gram-negative bacterium that is increasingly difficult to treat due to the emergence of multidrug resistant strains. In a recent article, Ding et al demonstrate that prekallikrein depletion in mice followed by intranasal instillation of K. pneumoniae leads to a reduced bacterial burden and prolonged host survival, together with evidence of reduced distant organ damage. These effects are apparently independent of the role of prekallikrein in the contact system, and are associated with transcriptional changes relevant to innate immunity in the lung, established prior to infection. This study highlights the importance of further investigating the role of prekallikrein and other contact cascade components in host defence to counter K. pneumoniae (and perhaps other pathogens), with an overall aim of identifying potential therapeutic targets relevant to pulmonary infection with such resistant pathogens. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Klebsiella Infections / Prekallikrein / Klebsiella pneumoniae Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Klebsiella Infections / Prekallikrein / Klebsiella pneumoniae Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article